GM will withdraw from the driverless taxi business, and the Cruise self-driving car division of GM will withdraw from the driverless taxi business. According to a statement on Tuesday, Cruise and GM's technical team will be combined to focus on developing autonomous driving and advanced driver safety technology for GM's future sales models. GM said that it will no longer provide funds for the development of self-driving taxis "considering the large amount of time and resources needed to expand its business scale and the increasingly fierce competition in the self-driving taxi market". The company said that giving up the development of self-driving taxis will save it more than $1 billion in annual costs.Huatai Securities: 600 million yuan of movie-watching consumption subsidies help the film to pick up. It is suggested to pay attention to the investment opportunities in the sector. Huatai Securities Research Report said that the National Film Bureau launched the "National Film Consumption Season for the benefit of the people" on December 9, and the "consumption season" will be from December 2024 to February 2025. A total of not less than 600 million yuan of movie-watching consumption subsidies will be invested; On the supply side, movies for the Spring Festival in 2025 are scheduled one after another, including Bears, Gods 2 and Legend of the Condor Heroes, etc., and the head players gather, so the box office for the Spring Festival in 2025 is expected to usher in a strong performance. Looking forward to 2025, both ends of supply and demand are expected to improve, and the fundamental inflection point of the cinema line plate will be pushed upward. It is suggested to pay attention to the investment opportunities in the plate.With the general election approaching, German Chancellor Angela Scholz supports reducing the value-added tax on basic groceries. German Chancellor Angela Scholz said in an interview on the evening of December 10th local time that he was in favor of reducing the value-added tax on basic groceries from 7% to 5% to help low-income families cope with inflation. The center-left leader also said that although the opposition Conservative Party has a big lead in the polls, he is confident of winning the early election on February 23rd.
Trump appointed TOM BARRACK as the US ambassador to Turkey.Guohai Securities gave Youyou Food Co., Ltd. the initial rating of buying.Non-bank deposit self-discipline initiative has landed, and bank financial management has welcomed "three changes". "Non-bank deposit self-discipline initiative involves a large scale of deposits, and some banks have begun to rectify. For the banking industry, the overall advantages outweigh the disadvantages. On the one hand, some configurable high-yield assets are gone; On the other hand, self-regulatory initiatives are beneficial to the bond market, and bond assets are an important direction for bank financial allocation. The most important thing is that in terms of risk-return characteristics, bank wealth management products are similar to interbank deposits, and it is expected that a large amount of funds will flow into the bank wealth management market from the interbank deposit market. " On December 10, a person from a financial company of a city commercial bank in the southern region bluntly told reporters.
US Treasury Department: US Treasury Secretary Yellen expressed appreciation for the close communication between the Ministry of Economic Affairs of Korea and the United States after the recent events in South Korea.More support policies for specialization and innovation are brewing. According to the data of the Ministry of Industry and Information Technology, up to now, China has cultivated a total of 14,600 "little giant" enterprises with specialization and innovation, and more than 140,000 small and medium-sized enterprises with specialization and innovation. Over 80% of the "Little Giant" enterprises are located in strategic emerging industrial chains such as integrated circuits and aerospace, and the number of enterprises in future industry-related fields such as artificial intelligence and low-altitude economy is nearly 5,000. The reporter was informed that the relevant departments will study and formulate guidance on building a mechanism to promote the development and growth of specialized and innovative small and medium-sized enterprises, issue guidance on cultivating high-quality enterprises, continue to increase support for the cultivation of specialized and innovative small and medium-sized enterprises, and promote the "expansion, quality improvement and strong chain" of specialized and innovative groups. (Economic Information Daily)Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.